Skip to main content

Advertisement

Table 2 Significant factors related to severe thrombocytopenia by univariate analysis

From: Factors linked to severe thrombocytopenia during antiviral therapy in patients with chronic hepatitis c and pretreatment low platelet counts

  Univariate analysis
Factors Platelets < 50 × 103/μL Platelets ≥ 50 × 103/μL Pvalue
Age, years 58 ± 11 57 ± 10 0.663
Male/female 9/7 56/53 0.463
BMI, kg/m2 23.37 ± 2.65 25.30 ± 3.19 0.022
ALB, g/dL 3.96 ± 0.30 4.16 ± 0.30 0.020
Total bilirubin, mg/dL 0.9 ± 0.4 0.8 ± 0.3 0.179
AST, U/L 147.44 ± 80.26 116.78 ± 62.33 0.145
ALT, U/L 200 ± 130 196 ± 116 0.909
ALK-p, U/L 113.20 ± 32.52 96.56 ± 31.62 0.065
Prothrombin time (INR) 1.07 ± 0.07 1.05 ± 0.05 0.111
WBC count,/cumm 4954 ± 1169 5303 ± 1215 0.338
Hgb, g/dL 13.86 ± 0.86 14.47 ± 1.49 0.101
Platelets, × 103/μL 100.63 ± 23.21 124.83 ± 18.74 < 0.001
Necroinflammatory activity, A0+A1/A2+A3 6/5 56/19 0.152
Fibrosis status, F1+F2/F3+F4 4/8 29/50 0.547
Cirrhosis, yes/no 5/11 23/86 0.269
Splenomegaly yes/no (%) 5/11 22/86 0.247
HCV-RNA, log10 IU/mL 5.41 ± 1.42 6.09 ± 0.96 0.033
HCV genotype- 1/2 5/11 66/43 0.033
Peg-IFN-α-2a/-α-2b 6/10 42/67 0.583
Peg-IFN-α-2a dose, μg/week 180 ± 0 (n = 6) 179 ± 9 (n = 42) 0.705
Peg-IFN-α-2b dose, μg/week 89 ± 11 (n = 10) 93 ± 12 (n = 67) 0.370
Ribavirin dose, mg/day 811 ± 169 900 ± 166 0.079
Rate of PLT decline at week 2, % 38.46 ± 11.53 14.06 ± 21.85 < 0.001
  1. Abbreviations: ALB: albumin; ALK-p: alkaline phosphatase; AST: aspartate aminotransferase; BMI: body mass index; Hgb: hemoglobin; HCV: hepatitic C virus; Peg-IFN: peginterferon; PLT: platelet